2409 related articles for article (PubMed ID: 29297205)
1. Cyclophosphamide for connective tissue disease-associated interstitial lung disease.
Barnes H; Holland AE; Westall GP; Goh NS; Glaspole IN
Cochrane Database Syst Rev; 2018 Jan; 1(1):CD010908. PubMed ID: 29297205
[TBL] [Abstract][Full Text] [Related]
2. Cyclophosphamide in Patients with Systemic Sclerosis-associated Interstitial Lung Disease: A Systematic Review and Meta-Analysis.
Barnes H; Ghazipura M; Herman D; Macrea M; Knight SL; Silver RM; Montesi SB; Raghu G; Hossain T
Ann Am Thorac Soc; 2024 Jan; 21(1):122-135. PubMed ID: 37772975
[No Abstract] [Full Text] [Related]
3. Phosphodiesterase 5 inhibitors for pulmonary hypertension.
Barnes H; Brown Z; Burns A; Williams T
Cochrane Database Syst Rev; 2019 Jan; 1(1):CD012621. PubMed ID: 30701543
[TBL] [Abstract][Full Text] [Related]
4. Rituximab versus intravenous cyclophosphamide in patients with connective tissue disease-associated interstitial lung disease in the UK (RECITAL): a double-blind, double-dummy, randomised, controlled, phase 2b trial.
Maher TM; Tudor VA; Saunders P; Gibbons MA; Fletcher SV; Denton CP; Hoyles RK; Parfrey H; Renzoni EA; Kokosi M; Wells AU; Ashby D; Szigeti M; Molyneaux PL;
Lancet Respir Med; 2023 Jan; 11(1):45-54. PubMed ID: 36375479
[TBL] [Abstract][Full Text] [Related]
5. Rituximab versus cyclophosphamide for the treatment of connective tissue disease-associated interstitial lung disease (RECITAL): study protocol for a randomised controlled trial.
Saunders P; Tsipouri V; Keir GJ; Ashby D; Flather MD; Parfrey H; Babalis D; Renzoni EA; Denton CP; Wells AU; Maher TM
Trials; 2017 Jun; 18(1):275. PubMed ID: 28619061
[TBL] [Abstract][Full Text] [Related]
6. Pirfenidone in patients with unclassifiable progressive fibrosing interstitial lung disease: a double-blind, randomised, placebo-controlled, phase 2 trial.
Maher TM; Corte TJ; Fischer A; Kreuter M; Lederer DJ; Molina-Molina M; Axmann J; Kirchgaessler KU; Samara K; Gilberg F; Cottin V
Lancet Respir Med; 2020 Feb; 8(2):147-157. PubMed ID: 31578169
[TBL] [Abstract][Full Text] [Related]
7. Pulmonary rehabilitation for interstitial lung disease.
Dowman L; Hill CJ; May A; Holland AE
Cochrane Database Syst Rev; 2021 Feb; 2(2):CD006322. PubMed ID: 34559419
[TBL] [Abstract][Full Text] [Related]
8. Mycophenolate in Patients with Systemic Sclerosis-associated Interstitial Lung Disease: A Systematic Review and Meta-Analysis.
Herman D; Ghazipura M; Barnes H; Macrea M; Knight SL; Silver RM; Montesi SB; Raghu G; Hossain T
Ann Am Thorac Soc; 2024 Jan; 21(1):136-150. PubMed ID: 37027538
[No Abstract] [Full Text] [Related]
9. Stem cell transplantation for systemic sclerosis.
Bruera S; Sidanmat H; Molony DA; Mayes MD; Suarez-Almazor ME; Krause K; Lopez-Olivo MA
Cochrane Database Syst Rev; 2022 Jul; 7(7):CD011819. PubMed ID: 35904231
[TBL] [Abstract][Full Text] [Related]
10. Longitudinal Changes in Quantitative Interstitial Lung Disease on Computed Tomography after Immunosuppression in the Scleroderma Lung Study II.
Goldin JG; Kim GHJ; Tseng CH; Volkmann E; Furst D; Clements P; Brown M; Roth M; Khanna D; Tashkin DP
Ann Am Thorac Soc; 2018 Nov; 15(11):1286-1295. PubMed ID: 30265153
[TBL] [Abstract][Full Text] [Related]
11. Pirfenidone in patients with progressive fibrotic interstitial lung diseases other than idiopathic pulmonary fibrosis (RELIEF): a double-blind, randomised, placebo-controlled, phase 2b trial.
Behr J; Prasse A; Kreuter M; Johow J; Rabe KF; Bonella F; Bonnet R; Grohe C; Held M; Wilkens H; Hammerl P; Koschel D; Blaas S; Wirtz H; Ficker JH; Neumeister W; Schönfeld N; Claussen M; Kneidinger N; Frankenberger M; Hummler S; Kahn N; Tello S; Freise J; Welte T; Neuser P; Günther A;
Lancet Respir Med; 2021 May; 9(5):476-486. PubMed ID: 33798455
[TBL] [Abstract][Full Text] [Related]
12. Efficacy and safety of nintedanib in patients with systemic sclerosis-associated interstitial lung disease treated with mycophenolate: a subgroup analysis of the SENSCIS trial.
Highland KB; Distler O; Kuwana M; Allanore Y; Assassi S; Azuma A; Bourdin A; Denton CP; Distler JHW; Hoffmann-Vold AM; Khanna D; Mayes MD; Raghu G; Vonk MC; Gahlemann M; Clerisme-Beaty E; Girard M; Stowasser S; Zoz D; Maher TM;
Lancet Respir Med; 2021 Jan; 9(1):96-106. PubMed ID: 33412120
[TBL] [Abstract][Full Text] [Related]
13. Opioids for the palliation of refractory breathlessness in adults with advanced disease and terminal illness.
Barnes H; McDonald J; Smallwood N; Manser R
Cochrane Database Syst Rev; 2016 Mar; 3(3):CD011008. PubMed ID: 27030166
[TBL] [Abstract][Full Text] [Related]
14. Mycophenolate Mofetil Versus Placebo for Systemic Sclerosis-Related Interstitial Lung Disease: An Analysis of Scleroderma Lung Studies I and II.
Volkmann ER; Tashkin DP; Li N; Roth MD; Khanna D; Hoffmann-Vold AM; Kim G; Goldin J; Clements PJ; Furst DE; Elashoff RM
Arthritis Rheumatol; 2017 Jul; 69(7):1451-1460. PubMed ID: 28376288
[TBL] [Abstract][Full Text] [Related]
15. Efficacy of mycophenolate mofetil versus cyclophosphamide in systemic sclerosis-related interstitial lung disease: a systematic review and meta-analysis.
Ma X; Tang R; Luo M; Zeng Z; Shi Y; Tang B; Xiao R
Clin Rheumatol; 2021 Aug; 40(8):3185-3193. PubMed ID: 34080081
[TBL] [Abstract][Full Text] [Related]
16. Cyclophosphamide for Systemic Sclerosis-related Interstitial Lung Disease: A Comparison of Scleroderma Lung Study I and II.
Volkmann ER; Tashkin DP; Sim M; Li N; Khanna D; Roth MD; Clements PJ; Hoffmann-Vold AM; Furst DE; Kim G; Goldin J; Elashoff RM
J Rheumatol; 2019 Oct; 46(10):1316-1325. PubMed ID: 30770517
[TBL] [Abstract][Full Text] [Related]
17. Rituximab in connective tissue disease-associated interstitial lung disease.
Duarte AC; Cordeiro A; Fernandes BM; Bernardes M; Martins P; Cordeiro I; Santiago T; Seixas MI; Ribeiro AR; Santos MJ
Clin Rheumatol; 2019 Jul; 38(7):2001-2009. PubMed ID: 31016581
[TBL] [Abstract][Full Text] [Related]
18. Efficacy and safety of antifibrotic agents in the treatment of CTD-ILD and RA-ILD: A systematic review and meta-analysis.
Yang M; Wu Y; Liu X; Zhao C; Li T; Li T; Zhang X; Jiang H; Mao B; Liu W
Respir Med; 2023 Sep; 216():107329. PubMed ID: 37315742
[TBL] [Abstract][Full Text] [Related]
19. Outcome measurement instrument selection for lung physiology in systemic sclerosis associated interstitial lung disease: A systematic review using the OMERACT filter 2.1 process.
Roofeh D; Barratt SL; Wells AU; Kawano-Dourado L; Tashkin D; Strand V; Seibold J; Proudman S; Brown KK; Dellaripa PF; Doyle T; Leonard T; Matteson EL; Oddis CV; Solomon JJ; Sparks JA; Vassallo R; Maxwell L; Beaton D; Christensen R; Townsend W; Khanna D
Semin Arthritis Rheum; 2021 Dec; 51(6):1331-1341. PubMed ID: 34493396
[TBL] [Abstract][Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
